Composition for iontophoretic delivery of rotigotine
CA 2505040 C · Owner: Schwarz Pharma Ag · Inventors: Bouwstra, Johanna Aaltje; Wolff, Hans-Michael; Li, Gai Ling
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
By using a composition comprising rotigotine and at least one chloride salt in a concentration of 1 to 140 mmol/l, the composition having a pH of 4 to 6.5 in a iontophoretic device for the treatment of Parkinson's disease it became , possible to obtain a rotigotine flux across the human stratum corneum which was higher than the one previously obtained with conventional passive diffusion systems.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed November 21, 2003 and granted October 16, 2012. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended November 21, 2023.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by November 21, 2025.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.